The challenge to predict mobilized peripheral blood stem cells on the fourth day of G-CSF treatment in healthy donors: the predictive value of basal CD34+ cell and platelet counts

In recent years, the number of allogeneic (Allo) stem cell transplantations (SCTs) has progressively increased worldwide [1,2]. Mobilized peripheral blood (PB) stem cells (PBSCs), compared with bone marrow grafts, have a higher stem cell content, lead to faster engraftment [3,4], and are more convenient for collection and, as a consequence, the use of PBSCs grafts have significantly increased. Initially, there were concerns about mobilization in the allogeneic setting due to normal donor toxicity [5,6] and the risk for graft-versus-host disease in the recipient [7], but studies have demonstrated G-CSFs to be well-tolerated by healthy donors (HDs) without any effects on long-term survival [8].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research